A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Mascolini
M
M
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use; D019469:Indinavir; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use; D019259:Lamivudine; D009154:Mutation; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D000998:Antiviral Agents; D007376:Interleukin-2; D011725:Pyridines; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine; D006918:Hydroxyurea